Bruton tyrosine kinase (BTK), a member of the Tec tyrosine kinases family, plays a central role in B cell lymphomas, and BTK inhibitors are increasingly replacing chemotherapy-based regimens, particularly in patients with chronic lymphocytic leukemia and MCL. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.